Duncan Jason's Form 4 filing
Albireo Pharma, Inc. (ALBO) · filed Oct 25, 2021
- Accession no.
- 0001209191-21-061556
- Filed
- Oct 25, 2021
- Trade date
- Oct 22-25, 2021
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $9.08K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Duncan JasonCIK 0001741553 | Officer (Chief Legal Officer and GC) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 22, 2021 | Common Stock | SSaleDisposed | −95 | $28.85F2 | −$2,740.75 | 7,572 | Direct | |
| Oct 25, 2021 | Common Stock | SSaleDisposed | −217 | $29.21 | −$6,338.57 | 7,355 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.8350 to $28.8974, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
Referenced by the price of 1 transaction in Table I.